Details
Stereochemistry | RACEMIC |
Molecular Formula | C27H25F3N2O |
Molecular Weight | 450.4954 |
Optical Activity | ( + / - ) |
Defined Stereocenters | 0 / 1 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
OC(CCCN1CCC2=C(C1)C3=C(C=CC(F)=C3)N2C4=CC=C(F)C=C4)C5=CC=C(F)C=C5
InChI
InChIKey=OYGDOCFZQVGFIP-UHFFFAOYSA-N
InChI=1S/C27H25F3N2O/c28-19-5-3-18(4-6-19)27(33)2-1-14-31-15-13-26-24(17-31)23-16-21(30)9-12-25(23)32(26)22-10-7-20(29)8-11-22/h3-12,16,27,33H,1-2,13-15,17H2
Molecular Formula | C27H25F3N2O |
Molecular Weight | 450.4954 |
Charge | 0 |
Count |
|
Stereochemistry | RACEMIC |
Additional Stereochemistry | No |
Defined Stereocenters | 0 / 1 |
E/Z Centers | 0 |
Optical Activity | ( + / - ) |
Flutroline, an antipsychotic drug that was studied to treat patients with schizophrenia. Clinical trials have shown that the drug was a safe, effective, and 20 mg and above offered the best potential for optimal clinical effectiveness. However, information about the further development of this drug is not available.
Approval Year
Sample Use Guides
In Vivo Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/6141186
in single daily dosages of 1, 5, 10, 20, and 100 mg to 48 hospitalized schizophrenic patients over a period of four weeks
Route of Administration:
Oral
Substance Class |
Chemical
Created
by
admin
on
Edited
Sat Dec 16 17:50:14 UTC 2023
by
admin
on
Sat Dec 16 17:50:14 UTC 2023
|
Record UNII |
J922111J7P
|
Record Status |
Validated (UNII)
|
Record Version |
|
-
Download
Name | Type | Language | ||
---|---|---|---|---|
|
Official Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Common Name | English |
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
SUB07766MIG
Created by
admin on Sat Dec 16 17:50:15 UTC 2023 , Edited by admin on Sat Dec 16 17:50:15 UTC 2023
|
PRIMARY | |||
|
C026240
Created by
admin on Sat Dec 16 17:50:15 UTC 2023 , Edited by admin on Sat Dec 16 17:50:15 UTC 2023
|
PRIMARY | |||
|
70801-02-4
Created by
admin on Sat Dec 16 17:50:15 UTC 2023 , Edited by admin on Sat Dec 16 17:50:15 UTC 2023
|
PRIMARY | |||
|
51174
Created by
admin on Sat Dec 16 17:50:15 UTC 2023 , Edited by admin on Sat Dec 16 17:50:15 UTC 2023
|
PRIMARY | |||
|
100000080426
Created by
admin on Sat Dec 16 17:50:15 UTC 2023 , Edited by admin on Sat Dec 16 17:50:15 UTC 2023
|
PRIMARY | |||
|
J922111J7P
Created by
admin on Sat Dec 16 17:50:15 UTC 2023 , Edited by admin on Sat Dec 16 17:50:15 UTC 2023
|
PRIMARY | |||
|
CHEMBL57241
Created by
admin on Sat Dec 16 17:50:15 UTC 2023 , Edited by admin on Sat Dec 16 17:50:15 UTC 2023
|
PRIMARY | |||
|
C169998
Created by
admin on Sat Dec 16 17:50:15 UTC 2023 , Edited by admin on Sat Dec 16 17:50:15 UTC 2023
|
PRIMARY | |||
|
DTXSID30867946
Created by
admin on Sat Dec 16 17:50:15 UTC 2023 , Edited by admin on Sat Dec 16 17:50:15 UTC 2023
|
PRIMARY | |||
|
4816
Created by
admin on Sat Dec 16 17:50:15 UTC 2023 , Edited by admin on Sat Dec 16 17:50:15 UTC 2023
|
PRIMARY |
Related Record | Type | Details | ||
---|---|---|---|---|
|
ENANTIOMER -> RACEMATE | |||
|
ENANTIOMER -> RACEMATE |
Related Record | Type | Details | ||
---|---|---|---|---|
|
ACTIVE MOIETY |